- Open Access
Dosimetric comparison of 4 MeV and 6 MeV electron beams for total skin irradiation
Radiation Oncologyvolume 9, Article number: 197 (2014)
In this study, dosimetric aspects of TSEI consisting of a 4 MeV beam with no spoiler were investigated in comparison to a nominal 6 MeV beam with spoiler, and the potential for clinical applications was evaluated.
The TSEI technique is based on the Stanford technique, which utilizes a beam configuration of six-dual fields. MOSFETs were used to measure the optimal gantry angle, profile uniformity, and absolute dose at the calibration point. The depth dose curve of the central axis was measured in the treatment plane using EBT2 film. Photon contamination was measured as the dose at 5 cm depth in a solid water phantom relative to the maximum dose using a parallel plate ion chamber. A MOSFET dosimeter placed on the surface of a humanoid phantom, and EBT2 films inserted into a humanoid phantom were used to verify the TSEI commissioning.
Dosimetric aspects of the 4 MeV TSEI beam, such as profile uniformity (±10%) and relative photon contamination (<0.001%), were comparable to those of a 6 MeV TSEI beam. The relative depth dose of the 4 MeV electrons was 81.4% at the surface and 100% at 0.4 cm. For the 6 MeV electrons, the relative depth dose was 93.4% at the surface and 100% from 0.2 cm to 0.4 cm. The calculated B-factor of the 4 MeV TSEI beam was 1.55, and 1.53 for the 6 MeV TSEI. 80% of the prescribed dose was obtained at 0.22 cm depth for the 4 MeV TSEI beam and 0.53 cm for the 6 MeV TSEI beam in the humanoid phantom measurement.
The suggested 4 MeV beam for TSEI could be applied to shallow depth skin diseases and to electron boost as second treatment course.
Total skin electron irradiation (TSEI) was developed by Stanford University in the 1950s and introduced for the treatment of mycosis fungoides, the most common form of cutaneous T-cell lymphoma which generally affects the skin . Since then, TSEI has been considered to be one of the best treatments for mycosis fungoides and employed for various diseases confined to the skin [2–4]. TSEI has also been extended for the treatment of other cutaneous disease such as Kaposi’s sarcoma and scleromyxoedema [5–9]. The goal is to deliver a relatively uniform dose (e.g., ±10%) to the entire surface of the skin, and not to exceed total photon contamination of 0.7 Gy . In order to deliver the treatment dose at a shallow depth, relatively low energy electrons are considered for TSEI, which is commonly performed with a 6 MeV beam [11–15]. 6 MeV electrons attenuated through a beam spoiler and air are sufficient to deliver the treatment dose to the epidermis and dermis located at a depth of 0.5 cm from the skin surface . For 6 MeV beams the use of a spoiler as a beam scatter-energy degrader is essential to allow adequate skin and depth doses. Increase in surface dose and improved profile uniformity can be obtained by placing the spoiler in front of the patient or mounting it on the gantry head [3, 4, 10, 12, 16]. Proper selection and placement of a spoiler strongly influence the quality of patient treatment, since the spoiler material and position along the beam axis are important in determining the monitor units (MU), profile uniformity, depth dose and relative photon contamination over the treatment plane. The nominal energy for skin electron therapy should range from 4 MeV to 8 MeV [17–20]. Electrons lose approximately 2 MeV/(g/cm2) while passing through the spoiler and air at extended source to surface distance (SSD) so that initially 6 MeV electrons arrive at the patient with an energy of around 4 MeV [21, 22].
The modified Stanford technique has been used in the clinical implementation of TSEI . Our institution implemented TSEI treatment with a six-dual field technique using 6 MeV electrons with an acrylic spoiler of 1 cm and extended SSD of 380 cm.
In this study, TSEI consisting of a 4 MeV beam was investigated with no a spoiler and therefore had an obliquity factor larger than 6 MeV. This obliquity factor is called as B factor which is ratio the treatment skin dose to the calibration point dose for the Stanford technique . The electron energy at the treatment plane was approximately equal to that of an attenuated 6 MeV beam. Furthermore, it reduces the photon contamination. The comprehensive dosimetric aspects for the stated 4 MeV technique were investigated in comparison to the nominal 6 MeV technique, and its potential for clinical application was also investigated.
Geometric Conditions of TSEI
TSEI technique is based on the Stanford technique, which uses a beam configuration of six-dual fields. A Varian Trilogy linear accelerator (Varian Medical Systems, Palo Alto, CA) generated both electron beams (4 and 6 MeV) with field size of 34 × 34 cm2, operated under the high dose rate mode (1000 MU/min). In our treatment room, the distance from source to wall was 490 cm from the horizontal beam axis. The position of the spoiler, a home-made acrylic plate (1.05 g/cm2) of 106 × 205 × 1 cm3, was 30 cm from the treatment plane for 6 MeV, and was not used for 4 MeV. The SSD of 380 cm for TSEI was not influenced by scattering radiation from the walls of the treatment room. With an SSD of 380 cm the dual field was obtained by using two fields for which the gantry is located within ±20° to the 90° gantry angle, which is perpendicular to the treatment plane. Figure 1 presents the patient setup and geometric conditions of the dual field technique. The MOSFET (Best Medical Canada, Ottawa, ON) was cross-calibrated against a NIST-traceable PTW 31013 cylindrical ion chamber (PTW, Freiburg, Germany) in a 9 MeV electron beam, following AAPM TG-51 protocols . The energy dependence of the MOSFET dosimeters was tested before measurement. The MOSFET dosimeters used in this study showed reliable performance in accordance with the results of previous studies . First, the gantry angles which make the most uniform profile of the vertical axis were determined for each TSEI electron beam using the MOSFET measurement with spatial resolution of 0.5° in an acrylic plate located in the treatment plane.
Another home-made acrylic plate (1.05 g/cm2) of 160 × 205 × 1 cm3 which used as total body irradiation (TBI) treatment spoiler was applied as a phantom. The dosimetric measurement was performed by attaching the MOSFET on this phantom. The profile uniformity across and along the patient’s longitudinal axis, with optimized gantry angles for each electron beam, were investigated with spatial resolutions of 2 cm and 5 cm for a central area of 40 cm, and outside of a central area using the MOSFET measurements, respectively. The absolute dose at the calibration point, which was located in treatment plane, was also defined with MOSFET measurements.
The percentage depth dose (PDD) curve in Solid Water™ (GAMMEX RMI, Middleton, WI) of the central axis for the 4 MeV and 6 MeV TSEI beams was measured for dual fields in the treatment plane using radiochromic EBT2 film (ISP, Wayne, New Jersy, USA). The film was inserted in the center of solid water phantom of 10 cm parallel to the 90° gantry angle. Photon contamination for 4 MeV with no the spoiler, and 6 MeV with spoiler was measured as the dose at 5 cm depth in a solid water phantom relative to the maximum dose using the Advanced Markus parallel plate ion chamber, type M34045 (PTW, Freiburg, Germany). In order to prevent the cable-induced effects on ion chamber measurements in large electron fields, known as the “Cable effect”, lead shielding of 0.5 cm thickness was applied to the chamber cable .
Dosimetric commissioning and QA
Finally, with patient setup and geometric conditions of the six dual-field technique, it is essential to determine the multiplication factor (B-factor) for the delivered dose at the patient surface. This factor, which relates the treatment skin dose to the calibration point dose, was calculated from measurements from a MOSFET placed on the surface of a humanoid phantom (CIRS Inc., Norfolk, VA). Phantom setup was made identical to the treatment setup by changing the positions every 60° about the patient’s longitudinal axis. Eight MOSFETs were attached on the phantom’s surface; at each of four locations (anterior, posterior, left and right lateral) in both the chest section and the abdominal section.
Three EBT2 films were inserted in the head, chest, and abdominal sections of the humanoid phantom to verify the TSEI commissioning. The film was then scanned using an Epson 1000X flatbed scanner (Epson America, Inc. Long Beach, CA) and in-house software was used to assess the depth dose distribution and isodose curves within the phantom.
The optimized treatment fields were at 90 ± 18.5° and 90 ± 18° for 4 MeV with no spoiler and 6 MeV with spoiler, respectively. With these dual fields, the results of profile uniformity are shown in Figure 2. In the vertical (inferior to superior) profile, uniformity of ±10% was demonstrated for 4 MeV and 6 MeV TSEI beams up to the end of the spoiler from 20 cm above the floor. Thus, a wooden patient support device of 20 cm height was designed to reduce scatter from the floor, and to indicate the patient’s treatment positions. The profile variations of 4 MeV with no a spoiler are much greater than that of 6 MeV with a spoiler. In the horizontal (left to right) profile, uniformity of ±10% was demonstrated for 4 MeV and 6 MeV TSEI beams within 70 cm width. The profiles for both beams were similar and shaped like a parabola.
PDD and Photon contamination
With TSEI treatment fields, the relative depth dose of 4 MeV electrons was 81.4% at the surface and 100% at 0.4 cm. For 6 MeV electrons, the relative depth dose was 93.4% at the surface and 100% from 0.2 cm to 0.4 cm. The depth of maximum dose was identical for both TSEI beams since the maximum energy of 6 MeV electrons attenuated by the 1 cm spoiler was 4 MeV. The PDD results are shown in Figure 3. The 4 MeV electrons with no the spoiler had a maximum penetration depth 1.3 cm. For 6 MeV with the spoiler, the maximum penetration was 1.9 cm. The mean energy was calculated from R50 according to AAPM TG-70 . The mean energy was 2.9 MeV and 3.2 MeV for 4 MeV and 6 MeV TSEI beams, respectively. For photon contamination, the ion chamber detected a signal which was contaminated with some level of noise (<0.001%). Table 1 is a tabulation of the treatment beam parameters.
Phantom measurements and verification
During one cycle (two treatment days) of TSEI, MOSFET detectors placed on the surface of the humanoid phantom were irradiated based on calculated MUs at the calibration point using the six dual-field technique. The average measured doses at the eight points were normalized to the prescription dose (200 cGy). Table 2 summarizes the resulting dose verification for the 4 MeV TSEI beam. The dose difference was calculated between the normalized dose and prescription dose. The maximum dose discrepancy of in-vivo dosimetry was 8.5% higher than the prescription dose and within the acceptable tolerance level of 10%. The calculated B-factor of the 4 MeV TSEI beam was 1.55. Table 3 summarizes the resulting dose verification for the 6 MeV TSEI beam. The maximum dose discrepancy was 6.5% lower than the prescription dose. The calculated B-factor of the 6 MeV TSEI beam was 1.53. The B-factors were comparable for both TSEI beams in this study. Using the B-factor, the treatment MUs were finally determined for both TSEI beams. The films inserted in the humanoid phantom were used for relative dose measurements. The periphery of the film was uniformly irradiated from the TSEI beams. PDDs from the irradiated films are shown in Figure 4. The maximum dose occurred at the surface of the phantom. At all three parts of the phantom, PDDs of the 4 MeV TSEI beam were steeper than that of the 6 MeV TSEI beam. The depth at which 80% of the prescribed dose was 0.22 cm for 4 MeV TSEI and average 0.53 cm for 6 MeV TSEI, which was the average depth of three films. The maximum penetration depth of the TSEI beams were 1.5 cm and 2 cm for 4 MeV and 6 MeV TSEI beams, respectively.
The 4 MeV electron beam with no a spoiler was investigated in implementing a clinical TSEI in this study. The electron measurement at extended SSD has a larger uncertainty and more setup variation than the electron measurement with nominal SSD. Thus, all measurements were performed three times and the average of the values was applied in this study.
The comprehensive dosimetric aspects for the 4 MeV TSEI beam were compared to a nominal 6 MeV TSEI technique. The dosimetric aspects of the 4 MeV TSEI beam, such as profile uniformity and relative photon contamination, were comparable to those of the 6 MeV TSEI beam, which could be implemented a clinical treatment. In the PDD, however, 80% of the prescribed dose was obtained at 0.22 cm depth in humanoid phantom measurements, which was shallower than the epidermis and dermis locations of 0.5 cm. It is limited to use for large tumor in T3 stage of CTCL TNM classification.
The required penetration depth is usually thought to vary with the stage and type of disease and may vary over the body . It also depends on the part of the body, the epidermis is thinnest on the eyelids at 0.5 cm, and thickest on the palms and soles at 0.15 cm, and dermis is 0.03 cm on the eyelid and 0.3 cm on the back. The 4 MeV TSEI beam could be used for skin diseases located in shallow depths of less than 0.3 cm. Moreover, an electron boost was concurrently administered to under dosage regions such as the top of the patient’s head and perineum. The 4 MeV TSEI beam, therefore, could be also used for the second treatment course based on region of interest. On the other hand, increase of total MU causes treatment time to rise and longer treatment times may give rise to instability of patient posture.
The suggested 4 MeV beam for TSEI could be applied to shallow depth skin diseases and to electron boost as second treatment course.
Total skin electron irradiation
Source to surface distance
Percentage depth dose
Total body irradiation.
Karzmark CJ, Loevinger R, Steele RE, Weissbluth M: A technique for large-field, superficial electron therapy. Radiology 1960, 74: 633-644. 10.1148/74.4.633
Desai K, Pezner R, Lipsett J, Vora N, Luk K, Wong J, Chan S, Findley D, Hill L, Marin L: Total skin electron irradiation for mycosis fungoides: relationship between acute toxicities and measured dose at different anatomic sites. Int J Radiat Oncol Biol Phys 1988, 15: 641-645. 10.1016/0360-3016(88)90306-9
Diamantopoulos S, Platoni K, Dilvoi M, Nazos I, Geropantas K, Maravelis G, Tolia M, Beli I, Efstathopoulos E, Pantelakos P, Panayiotakis G, Kouloulias V: Clinical implementation of total skin electron beam (TSEB) therapy: a review of the relevant literature. Phys Medica 2011, 27: 62-68. 10.1016/j.ejmp.2010.09.001
Piotrowski T, Milecki P, Skorska M, Fundowicz D: Total skin electron irradiation techniques: a review. Postepy Derm Alergol 2013, 30: 50-55.
Chang JH, Kim IH: Role of radiotherapy in local control of non-AIDS associated Kaposi's sarcoma patients in Korea: a single institution experience. Radiat Oncol J 2012, 30: 153-157. 10.3857/roj.2012.30.4.153
Nisce LZ, Safai B, Poussin‒rosillo H: Once weekly total and subtotal skin electron beam therapy for Kaposi’s sarcoma. Cancer 1981, 47: 640-644. 10.1002/1097-0142(19810215)47:4<640::AID-CNCR2820470403>3.0.CO;2-S
Leung SW, Hsu HC, Huang PH: Total skin electron beam irradiation in scleromyxoedema. Br J Radiol 1998, 71: 84-86. 10.1259/bjr.71.841.9534705
Jones G, Wilson LD, Fox-Goguen L: Total skin electron beam radiotherapy for patients who have mycosis fungoides. Hematol Oncol Clin North Am 2003, 17: 1421-1434. 10.1016/S0889-8588(03)00108-4
Jones GW, Kacinski BM, Wilson LD, Willemze R, Spittle M, Hohenberg G, Handl-Zeller L, Trautinger F, Knobler R: Total skin electron radiation in the management of mycosis fungoides: Consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group. J Am Acad Dermatol 2002, 47: 364-370. 10.1067/mjd.2002.123482
Anacak Y, Arican Z, Bar-Deroma R, Tamir A, Kuten A: Total skin electron irradiation: evaluation of dose uniformity throughout the skin surface. Med Dosim 2003, 28: 31-34. 10.1016/S0958-3947(02)00235-2
Hwang U, Baek TS, Yoon M: Development of dose verification method for in vivo dosimtery in external radiotherapy. Korean J Med Phys 2014, 25: 23-30.
El-Khatib E, Hussein S, Nikolic M, Voss NJ, Parsons C: Variation of electron beam uniformity with beam angulation and scatterer position for total skin irradiation with the Stanford technique. Int J Radiat Oncol Biol Phys 1995, 33: 469-474. 10.1016/0360-3016(95)00112-C
Parida DK, Rath GK: Advantages and implications of high dose rate (HDR) total skin electron irradiation (TSEI) for the management of Mycosis Fungoides. Indian experience. Rep Pract Oncol Radiother 2013, 19: 104-108.
Schiapparelli P, Zefiro D, Massone F, Taccini G: Total skin electron therapy (TSET): a reimplementation using radiochromic films and IAEA TRS-398 code of practice. Med Phys 2010, 37: 3510. 10.1118/1.3442301
Holt J, Perry D: Some physical considerations in whole skin electron beam therapy. Med Phys 1982, 9: 769. 10.1118/1.595135
Gamble LM, Farrell TJ, Jones GW, Hayward JE: Composite depth dose measurement for total skin electron (TSE) treatments using radiochromic film. Phys Med Biol 2003, 48: 891. 10.1088/0031-9155/48/7/306
Braams R: Superficial radiation therapy of large skin areas. Dermatologica 1958, 117: 204-214. 10.1159/000255592
Meyler TS, Blumberg AL, Purser P: Total skin electron beam therapy in mycosis fungoides. Cancer 1978, 42: 1171-1176. 10.1002/1097-0142(197809)42:3<1171::AID-CNCR2820420321>3.0.CO;2-8
Fraass BA, Roberson PL, Glatstein E: Whole-skin electron treatment: patient skin dose distribution. Radiology 1983, 146: 811-814. 10.1148/radiology.146.3.6828698
Piotrowski T, Malicki J: The rotary dual technique for total skin irradiation in the treatment of mycosis fungoides – a description of the applied method. Rep Pract Oncol Radiother 2006, 11: 29-37. 10.1016/S1507-1367(06)71047-1
Nahum AE: Water/air mass stopping power ratios for megavoltage photon and electron beams. Phys Med Biol 1978, 23: 24-38. 10.1088/0031-9155/23/1/002
Ding GX, Rogers DW, Mackie TR: Calculation of stopping-power ratios using realistic clinical electron beams. Med Phys 1995, 22: 489-501. 10.1118/1.597581
Bao Q, Hrycushko BA, Dugas JP, Hager FH, Solberg TD: A technique for pediatric total skin electron irradiation. Radiat Oncol 2012, 7: 40. 10.1186/1748-717X-7-40
Khan FM: Electron Beam Therapy. In The Physics of Radiation Therapy. Volume 1. 4th edition. Edited by: Pine J, Murphy J, Panetta A, Larkin J. Philadelphia: Lippincott Williams & Wilkins; 2010:264-314.
Almond PR, Biggs PJ, Coursey BM, Hanson WF, Huq MS, Nath R, Rogers DW: AAPM’s TG-51 protocol for clinical reference dosimetry of high-energy photon and electron beams. Med Phys 1999, 26: 1847-1870. 10.1118/1.598691
Ciocca M, Piazzi V, Lazzari R, Vavassori A, Luini A, Veronesi P, Galimberti V, Intra M, Guido A, Tosi G, Veronesi U, Orecchia R: Real-time in vivo dosimetry using micro-MOSFET detectors during intraoperative electron beam radiation therapy in early-stage breast cancer. Radiother Oncol 2006, 78: 213-216. 10.1016/j.radonc.2005.11.011
Fiorino C, Cattaneo GM, Del Vecchio A, Fusca M, Longobardi B, Signorotto P, Calandrino R: Cable-induced effects on plane-parallel ionization chamber measurements in large clinical electron beams. Med Dosim 1994, 19: 73-76.
Gerbi BJ, Antolak JA, Deibel FC, Followill DS, Herman MG, Higgins PD, Huq MS, Mihailidis DN, Yorke ED, Hogstrom KR, Khan FM: Recommendations for clinical electron beam dosimetry: supplement to the recommendations of Task Group 25. Med Phys 2009, 36: 3239-3279. 10.1118/1.3125820
Hoppe RT, Cox RS, Fuks Z, Price NM, Bagshaw MA, Farber EM: Electron-beam therapy for mycosis fungoides: the Stanford University experience. Cancer Treat Rep 1979, 63: 691-700.
This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (No. 2014M2B2A4031164).
The authors declare that they have no competing interest.
BSA drafted the manuscript. BSA and SYP collected and analysed all measurement data. SJY conceived of the concept of the study and oversaw its completion. JMP and IHK reviewed the TSEI commissioning and determined whether suggested techniques were clinically acceptable or not. JIK participated in all aspects of its design and coordination and drafted the manuscript. All authors read and approved the final manuscript.
So-Yeon Park, Beom Seok Ahn contributed equally to this work.